Blog: Nestle receives green light on Pfizer deal
Michelle Russell | 6 November 2012
Swiss food group Nestle today (6 November) received approval from the Chinese Ministry of Commerce for its US$11.85bn deal to acquire Pfizer's infant nutrition business.
The approval brings Nestle another step closer to completing the acquisition, which was announced in April this year, enabling the world's largest infant nutrition group to extend its lead in this fast-growing category.
Pfizer Nutrition operates in more than 60 countries globally and 85% of sales are generated in emerging markets, meaning the acquisition effectively fills in the blanks on the map for Nestle. It will provide the company with increased scale in a high-growth, high-margin, category in fast-growing developing markets, CEO Paul Bulcke told investors as it emerged as victor of competitive auction process.
Nestle beat companies including Danone and Mead Johnson to seal the agreement. The next hurdle, however, is to receive approval from anti-trust bodies in several countries in order to fully complete the acquisition.
In the sustainability arena, objective endorsement by a third party, particularly an NGO with credibility levels among consumers that even Unilever can only dream of, is an extremely valuable commodit...
An eye-catching tech move from Tesco has been revealed this week - and one that has echoes of one of Amazon's latest initiatives in the US....
Danone has appointed a new executive to lead its early life nutrition business, which features brands including Aptamil and Nutrilon....
- Work on sugar could stir more clean-label concerns
- Are consumers getting tired of consuming?
- Rise of prepared foods in US grocers - analysis
- Hershey results, outlook, M&A - the top takeaways
- Free-from firm BFree Foods - bitesize interview
- Nestle, R&R Ice Cream finalise joint venture plans
- Hershey buys company behind BarkThins brand
- Fazer buys European biscuit brands from Mondelez
- Mondelez sees stronger margins, LFL growth
- Young's eyeing new channels, M&A